ArticleTranslational andrology and urology2025
First-in-human study of DGPR1008 for intraoperative fluorescence imaging of prostate-specific membrane antigen-positive prostate cancer in patients undergoing radical prostatectomy.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- De-escalation surgery for localized prostate cancer: rationale and future direction of precision prostatectomy.Current opinion in urology · 2026Review
- Sarcosine-Based Pharmacokinetic Optimization and Fluorescent Dye Library Evaluation of Dual-Labeled PSMA Inhibitors for Fluorescence-Guided Surgery.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostate cancer (PCa) precise surgical resection remains a critical challenge due to positive margins compromising outcomes. This study sought to explore the safety and efficacy of DGPR1008, a novel near-infrared (NIR) prostate-specific membrane antigen (PSMA)-targeted fluorescent contrast agent, in fluorescence-guided surgery (FGS) of PCa. Methods: This single-center, open-label, prospective, single-arm, exploratory study was carried out in The Fourth Affiliated Hospital of Soochow University, China. Patients newly diagnosed with PCa (a Gleason score ≥7) were eligible for enrollment. All patients underwent laparoscopic radical prostatectomy (LRP) with pelvic lymph node dissection (PLND) using DGPR1008. Four dose cohorts were studied: dose cohort A, which received 0.06 mg/kg of DGPR1008 24 h preoperatively; dose cohort B, which received 0.03 mg/kg of DGPR1008 24 h preoperatively; dose cohort C, which received 0.03 mg/kg of DGPR1008 12 h preoperatively, and dose cohort D, which received 0.045 mg/kg of DGPR1008 24 h preoperatively. Safety and efficacy were assessed. Results: From July, 2023 to January, 2024, 14 eligible patients were included in the study. In total, 32 adverse events (AEs) were observed. One patient (7.1%) presented with four serious adverse events (SAEs), including urinary fistula, infected lymphocele, wound complications, and acute exacerbation of chronic obstructive pulmonary disease. None of the AEs or SAEs was found to be associated with the administration of DGPR1008. Compared with the other dose cohorts, DGPR1008 showed the highest sensitivity (80.6%) for detecting PCa Conclusions: DGPR1008 is safe and well tolerated, and may be used in the intraoperative identification of primary PCa and positive surgical margins. Dose cohort B (0.03 mg/kg, 24 h preoperatively) is optimal for efficacy and TBR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.